BSE List Price : ₹733.95

NSE List Price : ₹730.00

subscription

Category	Times
QIBs	213.08x
HNIs	116.72x
Retail	15.65x
Total : 93.72x

IPO Market Lot(s) Distribution

Application	Lot Size	Shares	Amount
Retail Minimum	1	25	₹14,825
Retail Maximum	13	325	₹192,725
S-HNI Minimum	14	350	₹207,550
S-HNI Maximum	67	1,675	₹993,275
B-HNI Minimum	68	1,700	₹1,008,100

About the Company

Sudeep Pharma Limited, established in 1989, stands among the foremost producers of excipients and specialty ingredients catering to the pharmaceutical, food, and nutrition sectors. The organization plays a pivotal role in enhancing the global healthcare framework, distributing an extensive portfolio of over 200 products to more than 100 countries. Leveraging proprietary in-house technologies—including encapsulation, spray drying, granulation, trituration, liposomal processing, and precision mixing—the company drives consistent innovation. Operations are aligned across two strategic business segments: Pharmaceutical, Food & Nutrition, and Specialty Ingredients. Additionally, the company operates six advanced manufacturing facilities with a consolidated production capacity of 50,000 MT.

Company Financial Report

_{Amount ₹ in Crores}

Period Ended	Revenue	Expense	PAT	Assets
2022	₹351.00	₹282.46	₹49.80	₹345.00
2023	₹438.26	₹352.28	₹62.32	₹420.11
2024	₹465.38	₹290.56	₹133.15	₹513.87
2025	₹511.33	₹328.48	₹138.69	₹717.17
June 2025	₹130.08	₹86.00	₹31.27	₹922.26

Company Promoter

Sujit Jaysukh Bhayani

Avani Sujit Bhayani

Shanil Sujit Bhayani

Sujeet Jaysukh Bhayani HUF

Riva Resources Private Limited And Bhayani Family Trust

Know before investing

• • Strengths

  A distinguished global customer base supported by long-standing relationships with key clients.

  State-of-the-art manufacturing facilities that are fully equipped and compliant with relevant regulatory standards.

• • Risks

  A significant concentration risk exists as the top 10 customers account for more than 35% of total revenue.

  Any quality shortcomings or audit non-compliance could result in loss of orders and potential reputational damage.

Objects of the Issue & Utilisation of proceeds

Capital expenditure towards procurement of machinery for the production line located at Nandesari Facility.

General corporate purposes.

Company  Address

Sudeep Pharma Ltd.
129/1/A,
GIDC Estate,
Nandesari,
Vadodara, Gujarat, 391340
Phone: +91 265 284 0656
Email: cs.sudeep@sudeepgroup.com
Website: https://www.sudeeppharma.com/

IPO Registrar

MUFG Intime India Pvt. Ltd.
Phone: +91-22-4918 6270
Email: sudeeppharma.ipo@in.mpms.mufg.com
Website: https://in.mpms.mufg.com/Initial_Offer/public-issues.html

IPO Review

May Apply : Backed by strong manufacturing capacity, diversified verticals, advanced proprietary technologies, and expansive global distribution, indicating resilient growth potential and stable scalability.